Physician profile
David Goldberg
NPI 1578543781
$4,943.29
in general payments reported to CMS, 2019-2025
22 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.08 · 2020: $34.60 · 2021: $184 · 2022: $2,245 · 2023: $1,691 · 2024: $226 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,488 · Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,487.50 |
| Food and Beverage | $931.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,890.81 | 2021-2023 | Tepezza |
| Amgen INC. | $423.13 | 2024-2025 | Tepezza, Uplizna |
| Regeneron Healthcare Solutions, INC. | $103.86 | 2023-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $94.10 | 2020-2025 | Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $54.08 | 2023-2024 | Xipere, Infuse, Biotrue |
| Astellas Pharma US INC | $54.06 | 2024-2025 | Izervay |
| Merz Pharmaceuticals, LLC | $43.05 | 2022-2024 | Xeomin |
| Glaukos Corporation | $38.27 | 2025 | Idosetr |
| Merz North America, INC. | $34.38 | 2019 | |
| Allergan, INC. | $22.64 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.36 | 2020 | |
| Alimera Sciences, INC. | $20.89 | 2023 | Iluvien |
| Rayner Intraocular Lenses Limited | $19.15 | 2023 | Rayone Emv, Rayone Aspheric, Omidria |
| Argenx US, INC. | $18.98 | 2023 | Vyvgart |
| Genentech USA, INC. | $17.39 | 2025 | Vabysmo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $17.03 | 2025 | Dextenza |
| Ani Pharmaceuticals, INC. | $14.33 | 2024 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $14.23 | 2023 | Syfovre |
| Eyevance Pharmaceuticals LLC | $13.85 | 2022 | |
| Spark Therapeutics, INC. | $12.98 | 2019 | |
| Shire North American Group INC | $12.89 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.